SCHEMBL3532867

SCHEMBL3532867

CCOc1nc(-c2ccc3ccc(-c4ccccc4)nc3c2)c2c(Cl)nccn12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 19/20 0.56
CYP3A4 P08684 9/20 0.51
INSR P06213 3/20 0.47
MAPK3 P27361 2/20 0.47
MAPK1 P28482 2/20 0.47
KDR P35968 2/20 0.47
RIPK2 O43353 1/20 0.47
ROCK2 O75116 1/20 0.47
LATS1 O95835 1/20 0.47
LCK P06239 1/20 0.47
LYN P07948 1/20 0.47
RET P07949 1/20 0.47
ABCB1 P08183 1/20 0.47
MET P08581 1/20 0.47
FGFR1 P11362 1/20 0.47
INSRR P14616 1/20 0.47
FECH P22830 1/20 0.47
MARK3 P27448 1/20 0.47
FLT4 P35916 1/20 0.47
MAP2K2 P36507 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4790404 0.88 IGF1R (0.56) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL3544220 0.88 IGF1R (0.73) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL401577 0.84 IGF1R (0.77) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL399559 0.82 IGF1R (0.60) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL397476 0.79 IGF1R (0.66) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL401619 0.79 IGF1R (0.66) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL397477 0.79 IGF1R (0.66) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL3540149 0.78 IGF1R (0.58) IGF1RINSRROCK2LYNRET
SCHEMBL396469 0.78 IGF1R (0.80) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL10256773 0.78 IGF1R (0.56) IGF1RCYP3A4INSRMAPK3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957496-B1 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2012-10-24 EP disclosed
US-7648987-B2 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-19 US disclosed
US-7648987-B2 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-19 US disclosed
US-7648987-B2 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-19 US disclosed
EP-1957496-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-08-20 EP disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 US disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149521-A1 Bicyclic protein kinase inhibitors CDK1, MAP4K2, MAP4K3 IGF1R 3009/4885CYP3A4 1115/4885INSR 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.